Reference Detail

Ref Type
PMID
Authors M Mita, A Mita, B Chmielowski, M Postow, E Hamilton, S Pant, Roger Waltzman, Eric Rowinsky, Michael Szarek, Foster Gonsalves, Isabel Kurth, Celia Andreu, Ilana Pollack, Daniel Mucida, Raissa Tanqueco, Sohail Tavazoie and Masoud Tavazoie
Title A phase 1 trial of RGX-104, a first-in-class immunotherapy targeting the liver-X nuclear hormone receptor (LXR), in patients with refractory malignancies
Journal Mol Cancer Ther
Vol
Issue
Date
URL http://mct.aacrjournals.org/content/17/1_Supplement/B001
Abstract Text Mol Cancer Ther 2018;17(1 Suppl):Abstract nr B001

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Treatment Approach
Gene Name Source Synonyms Protein Domains Gene Description Gene Role
Therapy Name Drugs Efficacy Evidence Clinical Trials
RGX-104 RGX-104 1 1
Drug Name Trade Name Synonyms Drug Classes Drug Description
RGX-104 RGX-104 activates liver-X nuclear hormone receptor (LXR), resulting in ApoE expression and enhancement of antitumor immunity (Mol Cancer Ther 2018;17(1 Suppl):Abstract nr B001).
Variant Impact Protein Effect Variant Description Associated with drug Resistance
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown Advanced Solid Tumor not applicable RGX-104 Phase I Actionable In a Phase I trial, RGX-104 demonstrated safety and preliminary efficacy, resulted in targeted gene expression in 100% (6/6), and activation of anti-tumor immune response in 83% (5/6) of patients with solid tumors refractory to anti-PD-1 therapy, with one renal cancer and one melanoma patient achieved stable disease (Mol Cancer Ther 2018;17(1 Suppl):Abstract nr B001). detail...